Larimar Therapeutics, Inc.
Pharmaceutical Preparations
Computed from SEC EDGAR filings and closing prices — not copied from any wealth ranking. Dataset . How we calculate this.
What Larimar Therapeutics, Inc. reports
Revenue and net income below are for fiscal period FY2019, the period label carried by this company’s own annual XBRL filings to the SEC. Fiscal years do not line up between companies — one company’s FY2026 can cover much the same months as another’s FY2025 — so compare the periods, not just the numbers.
Where the employee count comes from
Headcount comes from Yahoo Finance, not from a filing. The date beside it is the day we retrieved the figure — it is not the date the company counted its staff, and Yahoo does not publish that date. Unlike the SEC filings behind the other figures on this page, this one carries no open licence, so we publish the number and nothing else from that source.
Insiders at Larimar Therapeutics, Inc.
Shares is what each person last reported holding here.
Everyone below has filed at least one insider report against this company.
Value is that share count priced at the same closing price used everywhere else on this site. A row priced from only some of a person’s securities says so — we do not quietly present a partial sum as a complete one.
Rows are grouped by the role each person reports.
The role comes from the relationship boxes a person ticks on their own insider filings — officer, director, ten per cent owner — not from anything we infer. Somebody who is both an officer and a director appears once, in the combined group, so the row count still matches the figure at the top of this page. Where no filing states a role we say so instead of guessing one.
| Insider | Reported role | Shares | Value | Last action |
|---|---|---|---|---|
| Officers who also sit on the board 1 | ||||
| Carole Ben-Maimon | CEO | 399,432 | $1.53M | A Grant or award Jan 26, 2026 position reported |
| Directors 2 | ||||
Thomas Edward Hamilton
|
Board Member | 824,231 | $3.16M | P Open-market purchase Jul 6, 2026 position reported |
| Jeffrey W. Sherman | Board Member | 5,000 | $19.2K | P Open-market purchase Feb 27, 2026 position reported |
Recent insider transactions
Of the 6 rows we hold, 4 are open-market purchases (P) and 0 open-market sales — the only codes we count as buying or selling.
The rest — awards, shares withheld to pay tax, option exercises, gifts and so on — follow from an employment contract or a transfer arranged off-market, not from a decision to buy or sell, so counting them would turn this into a pay table.
A price of 0.00 is a real reported figure on gifts (G) and share awards (A) — not a gap in our data.
| Date | Insider | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jul 6, 2026 | Thomas Edward Hamilton | P Open-market purchase | 50,000 | $3.34 | $167.0K | SEC filing ↗ |
| Feb 27, 2026 | Jeffrey W. Sherman | P Open-market purchase | 5,000 | $5.00 | $25.0K | SEC filing ↗ |
| Feb 27, 2026 | Thomas Edward Hamilton | P Open-market purchase | 100,000 | $5.00 | $500.0K | SEC filing ↗ |
| Jan 26, 2026 | Carole Ben-Maimon | A Grant or award | 100,100 | $0.00 | $0 | SEC filing ↗ |
| Jan 22, 2025 | Carole Ben-Maimon | A Grant or award | 91,000 | $0.00 | $0 | SEC filing ↗ |
| Feb 16, 2024 | Thomas Edward Hamilton | P Open-market purchase | 57,208 | $8.74 | $500.0K | SEC filing ↗ |
From SEC Form 4 filings. Every row links to the filing it came from. How we calculate this.
What a Form 4 is
The report an officer, director or large shareholder must file after trading their own company’s stock.
Corporate ownership links — 9 filers hold a position
Who owns Larimar Therapeutics, Inc.
Each row is one filer naming this company.
Funds, trusts and other companies file the same ownership forms that executives do. Everything below is taken from those filings, with the position exactly as the filing states it.
Do not add these figures together. 9 of the positions below were reported on filings shared by several filers at once.
Why the same shares appear twice
On a joint filing every named filer is listed against the whole position, so the same block of stock appears under each name. Those rows are marked joint.
Filers holding a position in Larimar Therapeutics, Inc.
| Owner | Reported role | Shares | Filed |
|---|---|---|---|
| Deerfield Healthcare Innovations Fund, L.P. | Director,Other,TenPercentOwner | 35,606,974 joint | |
| DEERFIELD MANAGEMENT COMPANY, L.P. | Director,Other,TenPercentOwner | 35,606,974 joint | |
| Deerfield Mgmt HIF, L.P. | Director,Other,TenPercentOwner | 35,606,974 joint | |
| Deerfield Mgmt III, L.P. | Director,Other,TenPercentOwner | 35,606,974 joint | |
| Deerfield Mgmt IV, L.P. | Director,Other,TenPercentOwner | 35,606,974 joint | |
| Deerfield Mgmt L.P. | Director,Other,TenPercentOwner | 35,606,974 joint | |
| DEERFIELD PARTNERS, L.P. | Director,Other,TenPercentOwner | 35,606,974 joint | |
| Deerfield Private Design Fund III, L.P. | Director,Other,TenPercentOwner | 35,606,974 joint | |
| Deerfield Private Design Fund IV, L.P. | Director,Other,TenPercentOwner | 35,606,974 joint |
See the full ownership map — every entity that files as an owner of a US public company.
Subsidiaries — 1 legal entity
Subsidiaries of Larimar Therapeutics, Inc.
1 legal entity named in the subsidiary exhibit filed with this company’s most recent 10-K. . Filing on SEC.gov.
This is not the full list. SEC rules only require a company to name its significant subsidiaries.
What that leaves out
Smaller entities are left out of the exhibit entirely. A short list here means a short exhibit — it does not mean the company owns nothing else. Nothing on this page is inferred: every name below is copied from the filing.
| Subsidiary | Organised in |
|---|---|
| Zafgen Australia Pty Ltd. | Australia |
What counts as a subsidiary
A subsidiary is a separate legal entity this company controls; it is not the same thing as a brand, a division or an office. These entities do not file with the SEC in their own right, so there is no separate page to open for them.
Think a number here is wrong? Open the linked filing and compare — how to report it.
Sources and technical notes
Every figure on this page comes from filings to the U.S. SEC via EDGAR. Nothing here is estimated, and nothing is taken from press coverage or company websites.
Share count: cover page of the latest filing (dei:EntityCommonStockSharesOutstanding), taken from
Larimar Therapeutics, Inc.’s own filings and multiplied by our closing price.
Full method.
What that share count means
the share count the company itself prints on the cover of its most recent filing, as of the date it signed that filing.
We do not take a market cap from a data vendor, and we do not estimate one: the figure is a share count from Larimar Therapeutics, Inc.’s own SEC filings multiplied by the closing price we hold for the same stock.